Inoue, K., Masuda, N., Iwata, H., Takahashi, M., Ito, Y., Miyoshi, Y., . . . Toi, M. (2021). Japanese subpopulation analysis of MONARCH 2: Phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
Citación estilo ChicagoInoue, K., et al. Japanese Subpopulation Analysis of MONARCH 2: Phase 3 Study of Abemaciclib Plus Fulvestrant for Treatment of Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Breast Cancer That Progressed On Endocrine Therapy. 2021.
Cita MLAInoue, K., et al. Japanese Subpopulation Analysis of MONARCH 2: Phase 3 Study of Abemaciclib Plus Fulvestrant for Treatment of Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Breast Cancer That Progressed On Endocrine Therapy. 2021.